Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 3/2007

01.03.2007 | Review Article

The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions

verfasst von: Abdo Haddad, Mellar Davis, Ruth Lagman

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Adverse drug interactions are major causes of morbidity, hospitalizations, and mortality. The greatest risk of drug interactions occurs through in the cytochrome system. CYP3A4, the most prevalent cytochrome, accounts for 30–50% of drugs metabolized through type I enzymes.

Materials and methods

Palliative patients received medications for symptoms and co-morbidities, many of which are substrate, inhibitors, or promoters of CYP3A4 activity and expression. A literature review on CYP3A4 was performed pertinent to palliative medicine.

Discussion

In this state of the art review, we discuss the CYP3A4 genetics, and kinetics and common medications, which are substrates or inhibitor/promoters of CYP3A4.

Conclusion

We made some recommendations for drug choices to avoid clinically important drug interaction.
Literatur
1.
Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8(5):312–316PubMedCrossRef
2.
Richelson E (1998) Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. J Clin Psychiatry 59(Suppl 10):22–26PubMed
3.
Lippincott’s Pharmacology 2nd edition
4.
Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386–392PubMed
5.
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW et al (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42PubMedCrossRef
6.
Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30(8):883–891PubMedCrossRef
7.
8.
Finta C, Zaphiropoulos P (2000) The human cytochromeP450 3A locus. Gene evaluation by capture of downstream exons. Gene 260:13–23PubMedCrossRef
9.
Spina E, Scordo MG, D’Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17(5):517–538PubMedCrossRef
10.
Ito K, Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22(1):103–112PubMedCrossRef
11.
Ito K, Iwatsubo T (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together binding and transport. Annu Rev Pharmacol Toxicol 38:461–499PubMedCrossRef
12.
Von Moltke L, Greenblatt DJ, Schmider J, Wright E (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113–122CrossRef
13.
Galetin A, Ito K, Hallifax D, Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interaction. J Pharmacol Exp Ther 314(1):180–190PubMedCrossRef
14.
Houston JB, Galetin A (2005) Modeling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351–360PubMedCrossRef
15.
Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A4. Biochem Pharmacol 44:275–283PubMedCrossRef
16.
Shapiro L, Shear N (2002) Drug interactions: proteins, pump, and P-450s. J Am Acad Dermatol 47(4):467–484PubMedCrossRef
17.
Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18(2):100–107PubMedCrossRef
18.
Shaji K, Takashi I (1999) Pharmacokinetics of Haloperidol. Clin Pharmacokinet 37(6):435–456CrossRef
19.
Jann MW, Ereshefsky L, Saklad SR et al (1985) Effect of Carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 5:106–109PubMedCrossRef
20.
Arana GW, Goff DC, Friedman H et al (1986) Does Carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 143:650–651PubMed
21.
Goff DC, Midha KK, Brotman AW et al (1991) Elevation of plasma concentration of haloperidol after the addition of fluoxetine. Am J Psychiatry 148:790–792PubMed
22.
Syvälahti EKG, Taiminen T, Saarijärvi S et al (1997) Citalopram causes no significant alteration in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 25:24–32PubMed
23.
Lee MS, Kim YK, Lee SK et al (1998) A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 18:399–403PubMedCrossRef
24.
Herrlin K, Segerdahl M, Gustafsson LL, Kalso E (2000) Methadone, ciprofloxacin, and adverse drug reactions. Lancet 356(9247):2069–2070PubMedCrossRef
25.
Mclellan RA, Drobitch RK, Monshouwer M, Renton KW (1996) Fluoroquinlone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 36:1134–1138
26.
Ferrari A, Coccia CP, Bertolini A, Sternieri E (2004) Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 50(6):551–559PubMedCrossRef
27.
Westphal JF (2000) Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50(4):285–295PubMedCrossRef
28.
Hersh EV, Moore PA (2004) Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135(3):298–311PubMed
29.
Davis R, Markham A, Balfour J (1996) Ciprofloxacin: an update review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51:1019–1074PubMed
30.
Aminimanizani A, Beringer P, Jelliffe R (2001) Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 40(3):169–187PubMedCrossRef
31.
Johnson RE, Fudala PJ, Payne R (2005) Buprenorphine: considerations for pain management. J Pain Symptom Manage 29(3):297–326PubMedCrossRef
32.
Katz HI (1999) Drug interactions of the newer oral antifungal agents. Br J Dermatol 141(Suppl 56):26–32PubMedCrossRef
33.
Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB (2003) Voriconazole. Clin Ther 25(5):1321–1381PubMedCrossRef
34.
Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D (2003) No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 56(Suppl 1):30–36PubMedCrossRef
35.
Purkins L, Wood N, Kleinermans D, Love ER (2003) No clinically significant pharmacokinetic between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 56(Suppl 1):62–68PubMedCrossRef
36.
Boucher H, Groll A, Chiou C, Walsh T (2004) Newer systemic antifungal agents pharmacokinetics, saftey and efficacy. Drugs 64(18):1997–2020PubMedCrossRef
37.
Groll AH, Walsh TJ (2001) Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Ivestig Drugs 10(8):1545–1558CrossRef
38.
Pessayre D, Larrey D, Funck-Brentano C et al (1985) Drug interactions and Hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 16(Suppl A):181–194PubMed
39.
Von Rosensteil NA, Adam D (1995) Macrolide antibacterials. Drug interactions of clinical significant. Drug Safety 13(2):105–122
40.
Sonne J, Dossing M, Loft S, Anderson PB (1985) Antipyrine clearance in pneumonia. Clin Pharmacol Ther 37:701–703PubMedCrossRef
41.
Von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1995) Metabolism of drug by P450, 3A isoforms. Clin Pharmacokinet 29(Suppl 1):33–44
42.
Richelson E (2000) Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 75(9):933–942CrossRef
43.
Czock D, Keller F, Rasche FM, Häussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered Glucocorticoids. Clin Pharmacokinet 44(1):61–98PubMedCrossRef
44.
Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the united states: potential adverse interactions with anticancer agents. J Clin Oncol 22(12):2489–2503PubMedCrossRef
45.
Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St. John wort (hypericum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349–356PubMedCrossRef
46.
Westphal JF (2000) Macrolide-induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50(4):285–295PubMedCrossRef
47.
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44(3):279–304PubMedCrossRef
Metadaten
Titel
The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions
verfasst von
Abdo Haddad
Mellar Davis
Ruth Lagman
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0127-5

Weitere Artikel der Ausgabe 3/2007

Supportive Care in Cancer 3/2007 Zur Ausgabe

Supportive Care International

Factors associated with place of death of cancer patients in the Mexico City Metropolitan area

Original Article

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

Original Article

Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial

Original Article

The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone

Short Communication

Incident pain and analgesic consumption decrease after samarium infusion: a pilot study

Editorial

Editorial comment on: “The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer receiving palliative chemotherapy”. by Vincent et al.

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise